Scott Kopetz, MD, PhD, FACP, reviews the results of the phase 1b multicenter KISIMA-01 study, for which he presented preliminary results during the ESMO World Congress of Gastrointestinal Cancer 2021.
Scott Kopetz, MD, PhD, FACP, professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, reviews the results of the phase 1b multicenter KISIMA-01 study, for which he presented preliminary results during the ESMO World Congress of Gastrointestinal Cancer 2021.
The AP128 vaccine was well-tolerated as a monotherapy and in combination with the anti-PD-1 agent, ezabenlimab in patients with stage IV colorectal cancer treated in the KISIMA-01 clinical trial. Preliminary data also suggest this therapy may induce immune-mediated responses seen in the peripheral circulation and increased infiltration of TILs into liver metastases, explains Kopetz.
The KISIMA-01 study is ongoing and investigating the efficacy of the agent alone and in combination with ezabenlimab.
Retrospective Data Highlight Impact of Dose Escalation of Regorafenib in mCRC
May 9th 2024During a Case-Based Roundtable® event, Madappa Kundranda, MD, PhD, discussed recent retrospective studies that looked at outcomes of dose optimization of regorafenib for patients with relapsed/refractory advanced colorectal cancer in the first article of a 2-part series.
Read More
Responders to UGN-101 Have Positive RFS in Upper Tract Urothelial Cancer
May 5th 2024In patients at 15 centers who had upper tract urothelial cancer, those with no evidence of disease after UGN-101 induction had a 68% rate of 3-year recurrence-free survival, and this outcome did not differ based on tumor status, method of instillation, or treatment intent.
Read More